Type
Buy
Instrument
MARKSANS
Entry Price
₹19.6
Price@Trade
₹19.6
Target Price
₹24.45
Stop Price
₹18.8
Valid Till
Feb 20, 2020 3:20 PM
Margin
₹19.6 approx for 1 Qty
Status
Active
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum
MARKSANS Share Price Discussion
Marksans Pharma Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
MARKSANS Long Term Analysts Rating
- ★★
- ★★
- ★★
- ★★
- ★★
0/5 (0 Ratings)
MARKSANS Share Price *
19.55 +0.45 (2.36%)
* (quote may be delayed)
Find answers to all your questions on live MARKSANS message board: Is MARKSANS buy or sell? Should I buy MARKSANS shares? Why are MARKSANS shares falling? Should I invest in MARKSANS stock?
You can also check MARKSANS share price target recommended by brokerages.
MARKSANS Discussion Forum
@newsbot • Reputation: 1,933
An evening walk down D-St: Lack of any major step for NBFC crisis pulls Sensex 550 pts lower
Like
reply
Reply
@newsbot • Reputation: 1,933
Marksans Pharma rallies 5% after Goa unit receives EIR from USFDA
Like
reply
Reply
@newsbot • Reputation: 1,933
Marksans Pharma slips 4% post USFDA inspection at Goa facility
Like
reply
Reply
@chaudhary • Reputation: 196
Marksans Pharma reported better than street estimates of Q3 results. Company reported Q3 net profit Rs251.3mn (up 44% YoY), EBITDA margin 14.5% vs 13.2% (QoQ) and sales Rs2.48bn (up 14% YoY)
Like
reply
Reply
- NewsBotJun 6 10:08 PMAn evening walk down D-St: Lack of any major step for NBFC crisis pulls Sensex 550 pts lowerNewsBotJun 6 9:38 PMMarksans Pharma rallies 5% after Goa unit receives EIR from USFDANewsBotMar 7 7:52 PMMarksans Pharma slips 4% post USFDA inspection at Goa facilityNewsBotNov 17 10:47 PMThese 10 stocks moved between 10-35%: Do you own any?
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.